Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS105 combination therapy for advanced recurrent or metastatic gynecologic cancers
ChiCTR2400086368Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of JS105 in gynecological cancer, ovarian cancer, fallopian tube cancer (PFTC) and 3 more (2 cohorts), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Maximum tolerated dose, Recommended phase II dose and 2 more. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
JS105
03
Conditions
gynecological cancerovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2400086368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086368.